💡 Quick answer
The landmark clinical studies, treatment history and latest research for Minoxidil — fact-checked and sourced.
Research & evidence
How treatment evolved
1979FDA approves oral minoxidil (Loniten, Upjohn) for severe refractory hypertension; widespread hypertrichosis observed in treated patients becomes the basis for developing a topical hair-loss formulation.
1988FDA approves topical 2% minoxidil solution (Rogaine, Upjohn) as the first drug indicated for male androgenetic alopecia (vertex hair loss).
1991FDA approves topical 2% minoxidil for women with female pattern hair loss, extending the indication beyond men.
1997FDA approves the higher-strength topical 5% minoxidil solution (Extra Strength Rogaine) for men, shown to be more effective than 2%.
2006FDA approves 5% minoxidil foam (a propylene-glycol-free, once- to twice-daily vehicle) for men, improving tolerability; the 5% foam was later approved for women in 2014.
Key clinical studies
Olsen et al., 20022002
48-week double-blind, placebo-controlled, multicenter RCT; 393 men aged 18-49 with androgenetic alopecia (5% n=157, 2% n=158, placebo n=78), applied twice daily
At 48 weeks, 5% topical minoxidil was significantly superior to 2% and placebo in nonvellus hair count and in patient/investigator ratings of scalp coverage; 5% produced ~45% more hair regrowth than 2% and acted earlier, but caused more pruritus and local irritation.
Journal of the American Academy of Dermatology (JAAD) 2002;47(3):377-385
Lucky et al., 20042004
48-week double-blind, placebo-controlled, multicenter RCT; 381 women aged 18-49 with female pattern hair loss (5% n=153, 2% n=154, placebo n=74)
Both 2% and 5% minoxidil were superior to placebo for nonvellus hair count and investigator-assessed regrowth at 48 weeks; 5% was statistically superior to 2% only on the patient-assessed treatment-benefit endpoint, while causing more pruritus, local irritation, and hypertrichosis. Both were well tolerated with no systemic effects.
Journal of the American Academy of Dermatology (JAAD) 2004;50(4):541-553
van Zuuren et al. (Cochrane), 20162016
Systematic review/meta-analysis of 47 RCTs (5,290 participants) on female pattern hair loss; 17 trials evaluated minoxidil
Minoxidil (2% or 5%) roughly doubled the proportion of women achieving at least moderate hair regrowth versus placebo and increased mean total hair count per cm2; 2% and 5% showed no clear difference in efficacy. Adverse events were mild (itch, irritation, off-target hypertrichosis). Evidence was rated low-to-moderate quality.
Cochrane Database of Systematic Reviews 2016, CD007628.pub4
Latest research: The dominant 2023-2026 research direction has shifted toward low-dose oral minoxidil (typically 0.25-5 mg/day) as an alternative or adjunct to topical therapy, driven by adherence and absorption limits of topical formulations; a January 2025 international modified-Delphi consensus (JAMA Dermatology) standardized its off-label use, while studies focus on optimal dosing, combination regimens (e.g., with spironolactone or finasteride), and confirming cardiovascular safety. Topical research is also exploring sulfotransferase-based response prediction and novel vehicles to boost conversion to active minoxidil sulfate.
Summaries reflect published, peer-reviewed research and are not medical advice. See the linked sources for details.
Explore more
Self-check →Treatments →Transplant →Women →New →Hair Loss Causes →Hair-Loss Glossary →Hair-Loss Questions & Answers →Hair-Loss Ingredient Evidence Ratings →Hair Transplant Cost by City →Research →Browse all →
Not medical advice. General education only; it does not replace diagnosis or treatment by a licensed professional. Consult a board-certified dermatologist before starting, stopping or changing any treatment.
⚠️ When to see a doctor — don’t self-treat
- Sudden patchy or circular bald spots
- Redness, scaling, pus, pain or itch (possible scarring alopecia — treat urgently)
- Broken hairs or rapid loss
- Loss with body-wide signs (weight loss, fatigue, cycle changes, acne, extra hair)
- Loss right after a new medication
- Any hair loss in a child